Liminatus Pharma, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand Liminatus Pharma’s performance. My goal is to break down their complex filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Liminatus is a "pre-clinical" biotech company. They are currently in the lab phase, developing a cancer treatment called IBA101. This is a new type of antibody designed to help the immune system attack cancer cells.

Most current treatments accidentally damage healthy red blood cells and platelets. Liminatus is developing a version designed to target cancer cells while leaving healthy cells alone. They are a "bet on the future" company, relying on scientific breakthroughs rather than current sales. Their entire business centers on the research behind IBA101.

2. Financial performance

Because they have no products to sell, they do not generate profit. For the year ending December 31, 2025, the company reported zero revenue and a loss of $4.2 million, primarily driven by research and administrative costs. To maintain operations, they rely on loans from company insiders totaling $1.8 million, with interest rates ranging between 6% and 10%.

3. Major changes this year

The number of shares increased significantly. In June 2025, there were 26 million shares; by March 2026, that number reached nearly 44.9 million. This 72% increase reflects the issuance of 18.9 million new shares to raise $3.5 million in capital.

Scientifically, the company completed key safety studies in animals and is preparing to request FDA permission to begin human trials. Their research also indicates potential applications for the drug in treating chronic inflammation and weight loss, which could provide future business opportunities.

4. Financial health

The company is currently unable to support itself through operations and carries significant debt. At the end of 2025, they held $450,000 in cash. Given that upcoming human trials are estimated to cost $2.5 million, the company will need to secure additional funding.

5. Key risks

The primary risk is the company’s limited cash runway. Because they have no sales, they must consistently raise capital. If they cannot secure additional loans or sell more stock, they may run out of funds before trials are completed. Auditors have noted that the company’s current cash position creates uncertainty regarding its ability to continue operations over the next 12 months.

6. Future outlook

The company plans to initiate human safety trials in late 2026, followed by more complex testing in 2027. If these trials succeed, the company may become an attractive acquisition target for a larger pharmaceutical firm. Until then, the company will remain focused on raising capital and managing its debt obligations. Success is dependent on the clinical results of their research.

Note: This guide is for informational purposes and is not financial advice. Always do your own research before buying or selling stocks.